Literature DB >> 3390829

In situ hybridization analysis of acquisition and loss of the human multidrug-resistance gene.

D W Shen1, I Pastan, M M Gottesman.   

Abstract

The extent of multidrug-resistance of human KB carcinoma cell lines has been shown to be proportional to the level of expression of the MDR1 gene. Using an in situ hybridization analysis with 35S-labeled RNA probes, we have found that there is some heterogeneity in expression of the MDR1 gene from cell to cell, but that the average level of expression is proportional to the resistance of the cell line. In the absence of selective pressure, a colchicine-selected multidrug-resistant population with a highly amplified MDR1 gene loses its resistance in parallel with the loss of the amplified gene. Loss of resistance also parallels a decrease in MDR1 RNA expression in the whole cell population. Loss of MDR1 expression in this population is highly heterogeneous, with small clusters of cells maintaining expression even after the population as a whole has become relatively sensitive. This heterogenous loss of expression of the MDR1 gene is consistent with random segregation of amplified DNA segments in the selected cells. The analysis of MDR1 RNA expression by in situ hybridization which is validated by this study should be useful in the study of normal human tissue and tumor samples expressing the MDR1 gene.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390829

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Double minute chromosomes carrying the human multidrug resistance 1 and 2 genes are generated from the dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells.

Authors:  P V Schoenlein; D W Shen; J T Barrett; I Pastan; M M Gottesman
Journal:  Mol Biol Cell       Date:  1992-05       Impact factor: 4.138

2.  Expression of the mdr1 gene in human colorectal carcinomas: relationship with multidrug resistance inferred from analysis of human colorectal carcinoma cell lines.

Authors:  G Toffoli; A Viel; L Tumiotto; R Maestro; G Biscontin; M Boiocchi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Molecular cytogenetics of multiple drug resistance.

Authors:  P V Schoenlein
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro.

Authors:  K Mizuno; Y Furuhashi; O Maeda; M Iwata; T Misawa; M Kawai; T Kano; Y Tomoda
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Poised epigenetic states and acquired drug resistance in cancer.

Authors:  Robert Brown; Edward Curry; Luca Magnani; Charlotte S Wilhelm-Benartzi; Jane Borley
Journal:  Nat Rev Cancer       Date:  2014-09-25       Impact factor: 60.716

6.  Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.

Authors:  Megan R Ansbro; Suneet Shukla; Suresh V Ambudkar; Stuart H Yuspa; Luowei Li
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

7.  Expression of MDR1/P glycoprotein in human sarcomas.

Authors:  B Vergier; L Cany; F Bonnet; J Robert; A de Mascarel; J M Coindre
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

8.  Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers.

Authors:  D Schlaifer; G Laurent; S Chittal; T Tsuruo; S Soues; C Muller; J Y Charcosset; C Alard; P Brousset; C Mazerrolles
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

9.  In situ localization of the human multidrug-resistance gene mRNA using thymine-thymine dimerized single-stranded cDNA.

Authors:  I Sugawara; T Koji; K Ueda; I Pastan; M M Gottesman; P K Nakane; S Mori
Journal:  Jpn J Cancer Res       Date:  1990-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.